Bioretec Ltd, Company release, 12 October 2026 at 6:00 p.m. EEST
The following persons have been appointed to Bioretec's Shareholders' Nomination Board: Tor-Oskar Karlberg from Stephen Industries Inc Oy, Rami Vehmas from Keskinäinen Eläkevakuutusyhtiö Ilmarinen and Johan Hamström from Sp-Rahastoyhtiö Oy.
The Nomination Board has elected Tor-Oskar Karlberg as its chairperson at its organizational meeting on 12 October, 2026.
The chairperson of the Board of Directors of Bioretec acts as an expert to the Nomination Board without voting right.
In accordance with the Charter of the Shareholders' Nomination Board, the Shareholders' Nomination Board consists of three members. Each of the three largest shareholders as of the last working day in August has the right to nominate a member.
The Shareholders' Nomination Board is responsible for preparing and presenting to the Annual General Meeting a proposal on the members of the Board of Directors as well as proposals on the remuneration and number of members of the Board of Directors. The Shareholders' Nomination Board will submit its proposals for the 2027 Annual General Meeting to the Board of Directors by 30 January 2027.
Further inquiries
Panu Mikkonen, CFO, tel+358 50 483 3707
Tor-Oskar Karlberg, Investment Director, Stephen Industries Inc Oy + 358 50 910 6416
Certified adviser
Nordic Certified Adviser AB, +46 70 551 6729
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs™ product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com